Effect of combination therapy of a rapid-acting insulin secretagogue (glinide) with premixed insulin in type 2 diabetes mellitus

Satoru Yamada, Mari Watanabe, Osamu Funae, Yoshihito Atsumi, Ryuji Suzuki, Ken Yajima, Yoshiko Nakamura, Toshihide Kawai, Yoichi Oikawa, Akira Shimada

研究成果: Article

9 引用 (Scopus)

抄録

Aim: The effect of rapid-acting insulin secretagogues (glinides) on glycemic control when included with insulin therapy for type 2 diabetes remains uncertain. To examine this, we added glinide once a day to twice daily injections of premixed insulin. Research Design and Methods: Seventy-four type 2 diabetic patients, taking twice daily injections of premixed insulin and whose diabetic control was stable, were registered at 6 independent institutions. After a 3-month observation period, 60 patients were administered 10 mg mitiglinide or 90 mg nateglinide at lunchtime without changing their insulin regimen. After 12 weeks, administration of glinide was discontinued and observation was continued. HbA1c levels were measured at the start of glinide administration, after 12 weeks of glinide and at 12 weeks after discontinuation. Results: HbA1c improved from 7.72±0.66% to 7.55±0.71% (p <0.01) at Week 12 of glinide administration. Twelve weeks after discontinuation, HbA1c returned to the baseline level (7.72±0.81%). Conclusion: This study indicates that the addition of glinide once a day at lunchtime to twice daily injections of premixed insulin is effective for the treatment of type 2 diabetes.

元の言語English
ページ(範囲)1893-1897
ページ数5
ジャーナルInternal Medicine
46
発行部数23
DOI
出版物ステータスPublished - 2007 12 3

Fingerprint

Short-Acting Insulin
Type 2 Diabetes Mellitus
Insulin
Lunch
mitiglinide
nateglinide
Injections
Observation
Therapeutics
Research Design

ASJC Scopus subject areas

  • Internal Medicine

これを引用

Effect of combination therapy of a rapid-acting insulin secretagogue (glinide) with premixed insulin in type 2 diabetes mellitus. / Yamada, Satoru; Watanabe, Mari; Funae, Osamu; Atsumi, Yoshihito; Suzuki, Ryuji; Yajima, Ken; Nakamura, Yoshiko; Kawai, Toshihide; Oikawa, Yoichi; Shimada, Akira.

:: Internal Medicine, 巻 46, 番号 23, 03.12.2007, p. 1893-1897.

研究成果: Article

Yamada, S, Watanabe, M, Funae, O, Atsumi, Y, Suzuki, R, Yajima, K, Nakamura, Y, Kawai, T, Oikawa, Y & Shimada, A 2007, 'Effect of combination therapy of a rapid-acting insulin secretagogue (glinide) with premixed insulin in type 2 diabetes mellitus', Internal Medicine, 巻. 46, 番号 23, pp. 1893-1897. https://doi.org/10.2169/internalmedicine.46.0415
Yamada, Satoru ; Watanabe, Mari ; Funae, Osamu ; Atsumi, Yoshihito ; Suzuki, Ryuji ; Yajima, Ken ; Nakamura, Yoshiko ; Kawai, Toshihide ; Oikawa, Yoichi ; Shimada, Akira. / Effect of combination therapy of a rapid-acting insulin secretagogue (glinide) with premixed insulin in type 2 diabetes mellitus. :: Internal Medicine. 2007 ; 巻 46, 番号 23. pp. 1893-1897.
@article{4082d1759e874171aee714d1383fb58b,
title = "Effect of combination therapy of a rapid-acting insulin secretagogue (glinide) with premixed insulin in type 2 diabetes mellitus",
abstract = "Aim: The effect of rapid-acting insulin secretagogues (glinides) on glycemic control when included with insulin therapy for type 2 diabetes remains uncertain. To examine this, we added glinide once a day to twice daily injections of premixed insulin. Research Design and Methods: Seventy-four type 2 diabetic patients, taking twice daily injections of premixed insulin and whose diabetic control was stable, were registered at 6 independent institutions. After a 3-month observation period, 60 patients were administered 10 mg mitiglinide or 90 mg nateglinide at lunchtime without changing their insulin regimen. After 12 weeks, administration of glinide was discontinued and observation was continued. HbA1c levels were measured at the start of glinide administration, after 12 weeks of glinide and at 12 weeks after discontinuation. Results: HbA1c improved from 7.72±0.66{\%} to 7.55±0.71{\%} (p <0.01) at Week 12 of glinide administration. Twelve weeks after discontinuation, HbA1c returned to the baseline level (7.72±0.81{\%}). Conclusion: This study indicates that the addition of glinide once a day at lunchtime to twice daily injections of premixed insulin is effective for the treatment of type 2 diabetes.",
keywords = "Glinide, Glycemic control, Insulin treatment",
author = "Satoru Yamada and Mari Watanabe and Osamu Funae and Yoshihito Atsumi and Ryuji Suzuki and Ken Yajima and Yoshiko Nakamura and Toshihide Kawai and Yoichi Oikawa and Akira Shimada",
year = "2007",
month = "12",
day = "3",
doi = "10.2169/internalmedicine.46.0415",
language = "English",
volume = "46",
pages = "1893--1897",
journal = "Internal Medicine",
issn = "0918-2918",
publisher = "Japanese Society of Internal Medicine",
number = "23",

}

TY - JOUR

T1 - Effect of combination therapy of a rapid-acting insulin secretagogue (glinide) with premixed insulin in type 2 diabetes mellitus

AU - Yamada, Satoru

AU - Watanabe, Mari

AU - Funae, Osamu

AU - Atsumi, Yoshihito

AU - Suzuki, Ryuji

AU - Yajima, Ken

AU - Nakamura, Yoshiko

AU - Kawai, Toshihide

AU - Oikawa, Yoichi

AU - Shimada, Akira

PY - 2007/12/3

Y1 - 2007/12/3

N2 - Aim: The effect of rapid-acting insulin secretagogues (glinides) on glycemic control when included with insulin therapy for type 2 diabetes remains uncertain. To examine this, we added glinide once a day to twice daily injections of premixed insulin. Research Design and Methods: Seventy-four type 2 diabetic patients, taking twice daily injections of premixed insulin and whose diabetic control was stable, were registered at 6 independent institutions. After a 3-month observation period, 60 patients were administered 10 mg mitiglinide or 90 mg nateglinide at lunchtime without changing their insulin regimen. After 12 weeks, administration of glinide was discontinued and observation was continued. HbA1c levels were measured at the start of glinide administration, after 12 weeks of glinide and at 12 weeks after discontinuation. Results: HbA1c improved from 7.72±0.66% to 7.55±0.71% (p <0.01) at Week 12 of glinide administration. Twelve weeks after discontinuation, HbA1c returned to the baseline level (7.72±0.81%). Conclusion: This study indicates that the addition of glinide once a day at lunchtime to twice daily injections of premixed insulin is effective for the treatment of type 2 diabetes.

AB - Aim: The effect of rapid-acting insulin secretagogues (glinides) on glycemic control when included with insulin therapy for type 2 diabetes remains uncertain. To examine this, we added glinide once a day to twice daily injections of premixed insulin. Research Design and Methods: Seventy-four type 2 diabetic patients, taking twice daily injections of premixed insulin and whose diabetic control was stable, were registered at 6 independent institutions. After a 3-month observation period, 60 patients were administered 10 mg mitiglinide or 90 mg nateglinide at lunchtime without changing their insulin regimen. After 12 weeks, administration of glinide was discontinued and observation was continued. HbA1c levels were measured at the start of glinide administration, after 12 weeks of glinide and at 12 weeks after discontinuation. Results: HbA1c improved from 7.72±0.66% to 7.55±0.71% (p <0.01) at Week 12 of glinide administration. Twelve weeks after discontinuation, HbA1c returned to the baseline level (7.72±0.81%). Conclusion: This study indicates that the addition of glinide once a day at lunchtime to twice daily injections of premixed insulin is effective for the treatment of type 2 diabetes.

KW - Glinide

KW - Glycemic control

KW - Insulin treatment

UR - http://www.scopus.com/inward/record.url?scp=37549033471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37549033471&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.46.0415

DO - 10.2169/internalmedicine.46.0415

M3 - Article

C2 - 18057760

AN - SCOPUS:37549033471

VL - 46

SP - 1893

EP - 1897

JO - Internal Medicine

JF - Internal Medicine

SN - 0918-2918

IS - 23

ER -